Document Detail

Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
MedLine Citation:
PMID:  19460609     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. BACKGROUND: Despite benefits of clopidogrel in patients with NSTE-ACS undergoing percutaneous coronary intervention, this agent is often not administered upstream (before angiography) as recommended by the American College of Cardiology/American Heart Association guidelines because of potential bleeding in the minority of patients who require CABG. METHODS: The ACUITY trial enrolled 13,819 patients with NSTE-ACS undergoing early invasive management. The timing of clopidogrel initiation was per investigator discretion. A 5-day washout period before CABG was recommended for patients having received clopidogrel. RESULTS: Of 13,819 patients enrolled, 1,539 (11.1%) underwent CABG before discharge. Clopidogrel-exposed patients had a longer median duration of hospitalization (12.0 days vs. 8.9 days, p < 0.0001), but fewer adverse composite ischemic events (death, myocardial infarction, or unplanned revascularization) at 30 days; 12.7% vs. 17.3%, p = 0.01), with nonsignificantly different rates of non-CABG-related major bleeding (3.4% vs. 3.2%, p = 0.87) and post-CABG major bleeding (50.3% vs. 50.9%, p = 0.83) compared with those patients not administered clopidogrel. By multivariable analysis, clopidogrel use before CABG was an independent predictor of reduced 30-day composite ischemia (odds ratio: 0.67, 95% confidence interval: 0.48 to 0.92, p = 0.001) but not of increased post-CABG major bleeding (odds ratio: 0.98, 95% confidence interval: 0.80 to 1.19, p = 0.80). CONCLUSIONS: Clopidogrel administration before catheterization in patients with NSTE-ACS requiring CABG is associated with significantly fewer 30-day adverse ischemic events without significantly increasing major bleeding, compared to withholding clopidogrel until after angiography. These findings support the American College of Cardiology/American Heart Association guidelines for upstream clopidogrel administration in all NSTE-ACS patients, including those who subsequently undergo CABG. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158).
Ramin Ebrahimi; Cornelius Dyke; Roxana Mehran; Steven V Manoukian; Frederick Feit; David A Cox; Bernard J Gersh; E Magnus Ohman; Harvey D White; Jeffrey W Moses; James H Ware; A Michael Lincoff; Gregg W Stone
Related Documents :
23884199 - Characterization of anatomic ventricular tachycardia isthmus pathology after surgical r...
12965309 - Angiographic coronary diffuseness and outcomes in dialysis patients undergoing coronary...
16905139 - Renal dysfunction increases the risk of saphenous vein graft occlusion: results from th...
10387409 - In the queue for coronary artery bypass grafting: patients' perceptions of risk and 'ma...
15138089 - Robotic-assisted off-pump sole transmyocardial revascularization: case report.
6968859 - Multivariate discriminant analysis of the clinical and angiographic predictors of opera...
22193839 - Medical treatment of atrial fibrillation.
6979429 - The reasonable workup before recommending medical or surgical therapy: an overall strat...
8375409 - Right atrial contractile performance in patients with myocardial infarction.
Publication Detail:
Type:  Comment; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  53     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-22     Completed Date:  2009-06-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1965-72     Citation Subset:  AIM; IM    
University of California Los Angeles and the Greater Los Angeles VA Medical Center, Department of Medicine, Cardiology Section (111E), Los Angeles, California 90073, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / diagnosis,  drug therapy*,  surgery
Aged, 80 and over
Coronary Angiography
Coronary Artery Bypass / methods*
Coronary Care Units
Dose-Response Relationship, Drug
Follow-Up Studies
Heart Catheterization / methods*
Middle Aged
Platelet Aggregation Inhibitors / administration & dosage*
Preoperative Care / methods*
Prospective Studies
Ticlopidine / administration & dosage,  analogs & derivatives*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel
Comment On:
J Am Coll Cardiol. 2002 Oct 2;40(7):1366-74   [PMID:  12383588 ]
J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e157   [PMID:  17692738 ]
Comment In:
J Am Coll Cardiol. 2009 May 26;53(21):1973-4   [PMID:  19460610 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Echocardiography for cardiac resynchronization therapy selection: fatally flawed or misjudged?
Next Document:  Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure.